MAP2K1 P124S
|
Melanoma
|
MAP2K1 P124S
|
Melanoma
|
trametinib Sensitive: C3 – Early Trials
|
trametinib Sensitive: C3 – Early Trials
|
MAP2K1 P124S
|
Melanoma
|
MAP2K1 P124S
|
Melanoma
|
dabrafenib Resistant: C3 – Early Trials
|
dabrafenib Resistant: C3 – Early Trials
|
MAP2K1 P124S
|
Melanoma
|
MAP2K1 P124S
|
Melanoma
|
vemurafenib Resistant: C3 – Early Trials
|
vemurafenib Resistant: C3 – Early Trials
|
MAP2K1 P124S
|
Melanoma
|
MAP2K1 P124S
|
Melanoma
|
selumetinib Sensitive: C4 – Case Studies
|
selumetinib Sensitive: C4 – Case Studies
|
MAP2K1 P124S
|
Melanoma
|
MAP2K1 P124S
|
Melanoma
|
PLX4720 Resistant: D – Preclinical
|
PLX4720 Resistant: D – Preclinical
|